Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

NextEdge Admin

03 Nov 2024

2 min 17 sec

EvolveImmune Therapeutics,oncology,Partnership

AbbVie and EvolveImmune Therapeutics, a company focused on advancing immuno-oncology, have entered into a collaboration and option-to-license agreement aimed at developing multispecific biologics to target various types of cancer. This partnership will utilize EvolveImmune’s T-cell engager platform, EVOLVE, to create innovative antibody-based therapies for both solid and blood cancers.

The EVOLVE platform is designed to enhance the body’s immune response against tumors by delivering powerful and selective T-cell co-stimulation. This approach aims to overcome the common therapeutic obstacles, such as low tumor immunogenicity and T-cell dysfunction, which often limit the effectiveness of current immunotherapies in treating solid and hematologic cancers.

According to Jonathon Sedgwick, Ph.D., AbbVie’s senior vice president and global head of discovery research, this collaboration aligns with AbbVie’s commitment to advancing cancer treatments for patients with significant unmet needs. “We are excited to collaborate with the talented team at EvolveImmune to further advance their novel T-cell engager platform technology,” he noted.

Stephen Bloch, M.D., CEO of EvolveImmune, views the partnership as a significant endorsement of the EVOLVE platform, which uses a unique CD2 co-stimulation strategy to enhance T-cell engagement. "Our technology may offer clinically meaningful benefits for patients," Bloch stated.

Under the agreement, EvolveImmune will receive $65 million upfront in fees and equity investment, with the potential to earn up to $1.4 billion in option fees, milestone payments, and tiered royalties on future net sales.